Across the STEP trials, semaglutide 2.4 mg consistently demonstrated statistically and clinically significant weight loss compared with placebo [13, 38,39,40,41,42,43,44,45,46]
For investigational triple-agonist retatrutide (GLP-1/GIP/glucagon)
Geriatric individuals may require careful dosing adjustments because of age-associated changes in drug metabolism and increased adverse effects
Compounded drug products are not FDA-approved.Required Actions: Within 15 days, the company must respond in writing to the Office of Compounding Quality and Compliance (OCQC) with a description of how the company has addressed the violations, including removal of misleading language
FDA-Approved Tirzepatide Medications Tirzepatide is currently available in the United States only as FDA-approved prescription therapies: Mounjaro approved for the treatment of type 2 diabetes (FDA Prescribing Information)